Impax, Schering Patent Litigation Continues Despite Claritin-D Agreement
This article was originally published in The Tan Sheet
Executive Summary
Impax Labs' agreement to supply Schering-Plough with Claritin-D 12-Hour for OTC sale is not expected to attract Federal Trade Commission scrutiny due to its nonexclusivity provisions and lack of impact on pending patent litigation, the generics firm said
You may also be interested in...
Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System
Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers
Impax loratadine approval
Generics firm to begin shipments of loratadine 5 mg/pseudoephedrine 120 mg tablets to Schering-Plough, Wyeth "within days" of FDA's Jan. 30 approval of firm's ANDA (76-050). Impax Labs notes it has been manufacturing Claritin-D 12-Hour equivalent since November. Firm says it received "first-to-file" status with 180 days of generic marketing exclusivity triggered by first shipment. Under an agreement announced last June, Impax will manufacture, supply Schering with Claritin-D 12-Hour for OTC sale; product will reach shelves in early 2003, Schering says (1"The Tan Sheet" July 1, 2002, p. 4). Impax also has licensing, supply agreement with Alavert marketer Wyeth...
Schering OTC Claritin Coupons Appearing In Newspapers Dec. 15
Schering-Plough is offering consumers free samples of Claritin through a new Web site that became operational shortly after the drug's OTC approval